In summary, in this study of two large clinical trial cohorts, we find no evidence that LOF SNPs in the pattern recognition receptors FPR1, TLR3, and TLR4 are associated with differential benefit from oxaliplatin in CRC. This evidence concerns the gene TLR3 and colorectal carcinoma.